Kura Oncology Added to Nasdaq Biotechnology Index
December 18 2017 - 7:30AM
Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced that it has been selected
for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI),
effective prior to market open on Monday, December 18, 2017.
The Nasdaq Biotechnology Index (NBI) contains securities of
Nasdaq-listed companies classified as either biotechnology or
pharmaceutical, according to the Industry Classification Benchmark.
Companies in the NBI must meet eligibility requirements, including
minimum market capitalization and average daily trading volume,
among other criteria. The NBI is re-ranked annually and forms the
basis for a number of Exchange Traded Funds (ETFs), including the
iShares Nasdaq Biotechnology ETF. For more information about the
NBI, visit https://indexes.nasdaqomx.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura Oncology’s lead drug candidate is
tipifarnib, a farnesyl transferase inhibitor, which is currently
being studied in multiple Phase 2 clinical trials. The company’s
pipeline also includes KO-947, an ERK inhibitor, currently in a
Phase 1 trial, and KO-539, an inhibitor of the menin-MLL
protein-protein interaction, currently in preclinical testing. For
additional information about Kura Oncology, please visit the
company’s website at www.kuraoncology.com.
CONTACTS
Pete De SpainVice President, Investor Relations &Corporate
CommunicationsKura Oncology, Inc.(858)
500-8803pete@kuraoncology.com
Robert H. UhlManaging DirectorWestwicke Partners, LLC(858)
356-5932robert.uhl@westwicke.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024